FibroGen(FGEN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update • Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75% • Focus R&D investment on FG-3246 and PET46, a first-in-class anti-CD46 antibody-drug conjugate and companion PET imaging agent for metastatic castration-resistant prostate cancer (mCRPC) • Presented compelling prelimina ...